this post was submitted on 15 Oct 2024
15 points (89.5% liked)
Futurology
1804 readers
132 users here now
founded 1 year ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
Looks like it's a monoclonal antibody design to decrease inflammation. The target is people with persistent, low levels of inflammation and major depression.
My institution doesn't give access, but my first question would be whether they accounted for treatment for the underlying cause of the inflammation. Persistent inflammation can cause all sorts of issues and I suppose a treatment for relief is good, but why does it exist? Treating the underlying condition seems more prudent unless they don't know the cause.